Neuroplasticidad y depresión: una invitación a Enfermería para profundizar en nuevas estrategias de tratamiento

María del Carmen Ruiz-González; Alba Mata Agudo; Silvia Barragán Rodríguez; José Manuel Pérez Castillo

doi:10.58807/garnata20257939

María del Carmen Ruiz-González Unidad de Salud Mental Cartuja, Hospital Virgen de las Nieves. Granada, España
Alba Mata Agudo Unidad de Salud Mental Cartuja, Hospital Virgen de las Nieves. Granada, España
Silvia Barragán Rodríguez Unidad de Salud Mental Cartuja, Hospital Virgen de las Nieves. Granada, España
José Manuel Pérez Castillo Unidad de Salud Mental Cartuja, Hospital Virgen de las Nieves. Granada, España

DOI: https://doi.org/10.58807/garnata20257939

Palabras clave: Plasticidad neuronal, Depresión, Glutamato, Ketamina, Trastorno depresivo resistente al tratamiento

Key-words: Neuronal plasticity, Depression, Glutamate, Ketamine, Depressive disorder, Treatment-resistant

Resumen

Esta revisión sistemática examina la relación entre la neuroplasticidad, la depresión y la vía del glutamato, analizando estudios sobre los cambios cerebrales en pacientes deprimidos y el impacto de tratamientos como la ketamina. Los resultados indican que la modulación de la vía del glutamato, especialmente a través de antagonistas del receptor N-metil-D-aspartato (NMDA) y moduladores de ácido alfa-amino-3-hidroxi-5-metil-4-isoxazolepropiónico (AMPA), muestra mejoras significativas en los síntomas depresivos y la neuroplasticidad. Se concluye que la modulación del glutamato es prometedora para la depresión resistente al tratamiento, aunque se requiere más investigación.

Abstract

This systematic review examines the relationship between neuroplasticity, depression, and the glutamate pathway, analyzing studies on brain changes in depressed patients and the impact of treatments like ketamine. The results indicate that modulation of the glutamate pathway, particularly through NMDA receptor antagonists and AMPA modulators, shows significant improvements in depressive symptoms and neuroplasticity. It is concluded that glutamate modulation is promising for treatment-resistant depression, although further research is needed.

Bibliografía

World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: WHO; 2017. Disponible en: https://iris.who.int/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5). 5^ª ed. Washington, DC: American Psychiatric Publishing; 2013.

GBD 2019 Diseases and Injuries Colaboradores. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9. Fe de erratas en: Lancet. 2020; 396 (10262):1562. doi: 10.1016/S0140-6736(20)32226-1.

Duman, Ronald S; Aghajanian, George K. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012; 338 (6103): 68-72. doi: 10.1126/science.1222939.

Krystal, John H; Sanacora, Gerard; Duman, Ronald S. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2019; 86(5): 444-56. doi: 10.1016/j.biopsych.2013.03.026.

Zarate, Carlos A; Singh, Jaskaran B; Carlson, Paul J; Brutsche, Nancy E; et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856-64. doi: 10.1001/archpsyc.63.8.856.

Allen, Jessica; Balfour, Reuben; Bell, Ruth; Marmot, Michael. Social determinants of mental health. Int Rev Psychiatry. 2014; 26 (4): 392-407. doi: 10.3109/09540261.2014.928270.

Daly, Ella J; Trivedi, Madhukar H; Janik, Adam; Honglan, Yun; et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2019; 76(9): 893–903. doi: 10.1001/jamapsychiatry.2019.1189.

Tabuteau, Herriot; Jones, Amanda; Anderson, Ashley; Jacobson, Mark; Iosifescu, Dan V. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022; 179(7): 490–499. doi:10.1176/appi.ajp.21080800.

Fu, Dong-Jing; Ionescu, Dawn F; Li, Xiang; Lane, Rosanne; et al. Esketamine nasal spray for rapid reduction of major depressive disorder symptoms in patients who have active suicidal ideation with intent: double-blind, randomized study (ASPIRE I). J Clin Psychiatry. 2020;81(3):19m13191. doi:10.4088/JCP.19m13191.

Quiroz, Jorge A; Tamburri, Paul; Deptula, Dennis; Banken, Ludger; et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016; 73(7): 675–684. doi:10.1001/jamapsychiatry.2016.0838.

Popova, Vanina; Daly, Ella J; Trivedi, Madhukar; Cooper, Kimberly; et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6): 428–438. doi: 10.1176/appi.ajp.2019.19020172.

Domany, Yoav; Bleich-Cohen, Maya; Tarrasch, Ricardo; Meidan, Roi; et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomized, double-blind, placebo-controlled, proof-of-concept study. Br J Psychiatry. 2019; 214(1): 20–26. doi:10.1192/bjp.2018.196.

Neuroplasticidad y depresión: una invitación a Enfermería para profundizar en nuevas estrategias de tratamiento

Neuroplasticity and Depression: An invitation to Nursing to explore new treatment strategies

Resumen

Abstract

Bibliografía